#United States #New Orleans #Eli Lilly #retatrutide #Foundayo

Innovative Advances in Diabetes and Obesity Care

Eli Lilly and Company is set to present exciting new findings regarding its cardiometabolic portfolio at the upcoming American Diabetes Association's (ADA) 86th Scientific Sessions from June 5 to 8, 2026, in New Orleans. This conference serves as a platform for impactful discussions revolving around advancements in treatments for diabetes and obesity, and Lilly has a significant presence this year with its key medications: Foundayo (orforglipron), Mounjaro (tirzepatide), and retatrutide.

Key Findings on Foundayo

In recent Phase 3 trials, specifically within the ACHIEVE program, Foundayo—a novel oral GLP-1 receptor agonist—demonstrated remarkable results. Patients using Foundayo experienced notable reductions in A1C levels, outperforming standard treatments such as dapagliflozin. Notably, it achieved a reduction of up to 1.7% in A1C levels, compared to 0.8% with dapagliflozin over a 40-week period.

Moreover, patients taking Foundayo benefitted from significant weight loss, showcasing its potential to provide not only glycemic control but also contribute to weight management. In comparison to oral semaglutide, Foundayo resulted in a 73.6% greater relative weight loss after 52 weeks, indicating its promise as a frontrunner in oral incretin therapy.

Focus on Women’s Health

An intriguing aspect highlighted in the data is Foundayo's effect on women during different stages of menopause. Findings suggest that the medication supports significant weight loss and improved insulin sensitivity among peri-menopausal or post-menopausal women. This subgroup analysis showcases Lilly’s commitment to addressing the unique health challenges faced by women in the realm of cardiometabolic care.

The Emergence of Retatrutide

Lilly will also feature pivotal data on retatrutide, a first-in-class triple receptor agonist, which has shown remarkable efficacy in managing obesity and type 2 diabetes. Results from the TRIUMPH-1 study demonstrated that participants experienced a weight loss average of up to 70.3 lbs (28.3%) over 80 weeks, a transformative outcome for the obesity community.

In the TRANSCEND-T2D-1 study, retatrutide participants also exhibited a decrease in A1C levels by up to 2.0% and weight loss averaging 36.6 lbs (16.8%) over 40 weeks, reinforcing its potential as a comprehensive treatment option for patients dealing with multiple metabolic challenges.

Clinical Events and Investor Engagement

To further engage stakeholders, Lilly is hosting an investor event on June 6 at 6:00 PM CDT, where insights into the cardiometabolic health portfolio and key disclosures from the ADA meeting will be discussed. This event will be accessible through a live webcast, allowing broader participation and a deeper dive into the data.

Conclusion

The insights and results presented at the ADA 86th Scientific Sessions mark a significant step forward in redefining diabetes and obesity care through innovative treatment options. With options like Foundayo and retatrutide, Lilly aims to enhance the therapeutic landscape, providing personalized care tailored to the diverse needs of patients. As we look to the future, these developments signal a more inclusive and effective approach to managing cardiometabolic health challenges.

For more updates on the findings and access to presentations from the sessions, please visit Lilly's investor website post-conference.